Aurobindo Pharma has received its board approval to raise up to an amount of $350 million through issue shares to Qualified Institutional Buyers. The approval to issue shares under Qualified Institutional Placement (QIP) was secured at a meeting held on January 21, 2015.
Aurobindo Pharma manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retrovirals, CVS, CNS, Gastroenterologicals, and Anti-Allergics, supported by an outstanding R&D set-up.
